Optimer Pharmaceuticals, Inc. announced that it has completed the submission of its new drug application to the U.S. Food and Drug Administration for fidaxomicin to treat patients with Clostridium difficile infection and to prevent recurrences of CDI.
Shire plc announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase 3 trials studying the use of Firazyr for treatment of acute attacks of hereditary angioedema.
New research shows the NSAID Celebrex may help prevent some non-melanoma skin cancers from developing in patients who have pre-cancerous actinic keratoses lesions and are at high risk for having the disease.
A scientific report has found evidence of reduced activity of an energy-generating enzyme in deceased young adult brain donors who carry a common genetic risk factor for Alzheimer's disease.
Mayo Clinic researchers have shown why, in a minority of HIV patients, immune function improves despite a lack of response to standard anti-retroviral treatment. In these cases, researchers say, the virus has lost its ability to kill immune cells.
New research shows that anti-microbial medications are a common cause of drug-induced liver injury leading to acute liver failure, with women and minorities disproportionately affected.
The U.S. Food and Drug Administration has approved Octapharma USA’s investigational new drug application for octaplex as a fast track product for reversing anticoagulation therapy in patients needing urgent Surgery or invasive procedures.
BioClinica, Inc., a global provider of clinical trial management services, announced a strategic partnership with Kaizen Clinical Services, Inc., an oncology-focused contract research organization.
The National Comprehensive Cancer Network has been awarded a $2.1 million grant from Pfizer to develop a program to scientifically evaluate and define the clinical activity of axitinib in various tumor types.
Scripps Research Institute scientists have made a significant leap forward in the drive to find a way to safely reprogram mature human cells and turn them into stem cells, which can then change into other cell types, such as nerve, heart, and liver cells.
Janssen Pharmaceutica N.V., announced a research agreement to collaborate with GE Healthcare to develop non-invasive or minimally invasive diagnostic biosignatures to detect Alzheimer's disease prior to the onset of clinical symptoms.
Dilyx Biotechnologies’ OptiSol Protein Solubility Screening kit addresses a leading cause of inadvertent protein sample loss: protein aggregation. The kit combines an array of 96 test solutions having different pH, salt, and additives with array-based filtration technology.
Biotage has added ChemMatrix resins to its offering of peptide synthesis and purification products. ChemMatrix is a 100% PEG resin from Matrix Innovation that offers advantages over traditional PS and PEG based resins for solid phase peptide synthesis.
Selventa, which evolved from Genstruct, Inc. announced that it has changed its name and launched a re-branded Web site as part of an initiative to provide innovative solutions for its client partners.
Cisbio Bioassays announced the launch of the GluSense research and development program in partnership with the Functional Genomics Institute. The project, financed by France’s National Research Agency, will focus on the development of CNS drug discovery research tools.